YSBWPAUTOMATE

NanoMab is pleased to announce its collaboration in the EPSRC Programme for Next Generation Imaging and Therapy with Radionuclides (MITHRAS). London, June 5th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, is pleased to announce that it is participating as an Industrial Partner in the EPSRC Programme for Next [...]

NanoMab Enters into Agreement with University Hospital Aachen to initiate a Cancer Therapy Programme utilising next generation NM-02 radiopharmaceutical product. Translational Programme established for FIH late stage HER2 positive breast cancer in Q4 2020.   London, May 20th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced [...]

NanoMab appoints Paul Edwards as CEO and sets up in UK in preparation for  European clinical trial programme Precision oncology therapeutics company moves centre of operations from China London, April 28, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies via the development of next generation radiopharmaceuticals, today announced a [...]

Date: Aug 13th, 2019 NanoMab Announces First Breast Cancer Patient Dosed in FIH of 99mTc-NM-02 Shanghai, China, August 13th, 2019. NanoMab today announced dosing of the first patients for its FIH trial of 99mTc-NM-02 in patients with breast cancer at SGH. 99mTc-NM-02 is a camelid single domain antibody-based imaging agent for the non-invasive and [...]

Date: Aug 1st, 2019 NanoMab To Initiate FIH for 99mTc-NM-02 at SGH Shanghai, China, August 1st, 2019. NanoMab announced that it has decided to initiate FIH with 99mTc-NM-02, which is the company’s breast cancer program. The kick off meeting was held at Shanghai General Hospital (SGH). The primary objective of this study is to [...]

Date: June 24th, 2019 NanoMab Presents at SNMMI Anaheim, California, US, June 24th, 2019. Gitasha Chand, clinical research director of NanoMab presented NanoMab’s FIH data of 99mTc-NM-01 at the annual meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI). 99mTc-NM-01 is a camelid single domain antibody-based imaging agent for the non-invasive and whole [...]

Date: May 29th, 2019 NanoMab and Lantheus enter into License Agreement Regarding the Commercial Development of 99mTc-NM-01 Shanghai, China, May 29th, 2019. NanoMab announced a collaboration with Lantheus Medical Imaging, Inc. (LMI) to provide 99mTc-NM-01 as clinical research tool, together with support and analytics, to pharmaceutical companies and the largest academic centers conducting clinical [...]

Date: April 1st-3rd, 2019 Gary Cook won 2nd Oral Prize of British Nuclear Medicine Society London, UK, April 1st-3rd, 2019. Gary Cook, scientific advisor of NanoMab presented 99mTc-NM-01 clinical data at the annual meeting of British Nuclear Medicine Society (BNMS) and was awarded with 2nd Oral Prize for his presentation ‘Imaging Programmed Cell Death [...]

Date: Feb 22nd, 2019 NanoMab Publishes Clinical Research Paper on Journal of Nuclear Medicine Shanghai, China, February 22nd, 2019. NanoMab published its FIH data for the first 16 patients of 99mTc-NM-01 on Journal of Nuclear Medicine (JNM), titled ‘Early phase I study of a 99mTc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of [...]

Date: Feb 7th, 2019 NanoMab Enters into Agreement with Guy’s and St Thomas’ NHS Foundation Trust for Investigator Initiated Study London, UK, February 7th, 2019. NanoMab announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust on the investigator-initiated study for 99mTc-NM-01. The primary objective is to assess the change in PD-L1 expression [...]